Characterization of a V3 domain-specific neutralizing human monoclonal antibody that preferentially recognizes non-syncytium-inducing human immunodeficiency virus type 1 strains. 1995

M Schutten, and J P Langedijk, and A C Andeweg, and R C Huisman, and R H Meloen, and A D Osterhaus
Institute of Virology, Erasmus University Rotterdam, The Netherlands.

A type-specific human immunodeficiency virus type 1 (HIV-1)-neutralizing human monoclonal antibody (HuMAb MN215) is described that reacts with the V3 domain of a number of subtype B virus strains. Pepscan analysis indicated that amino acids at both sides of the tip of the V3 loop were involved in the binding of HuMAb MN215. The minimum epitope in a V3 sequence, obtained from the donor from whom the cell line originated, was 9 amino acids long and proved to be located at the C-terminal side of the tip of the loop. In a replacement Pepscan analysis, individual amino acids of the V3 loop important for binding of HuMAb MN215 were identified. Amino acids at positions 15 (H), 16 (I), 17 (G) and 18 (P) were found to be essential for binding of the antibody, whereas changes at positions 19 of G to N, 20 of R to K and 23 of F to L, as well as the addition of a negative charge at the C terminus, improved binding. Thus, amino acids involved in the binding of HuMAb MN215 are primarily located within highly variable regions of the V3 loop. HuMAb MN215 showed a higher affinity for the V3 domain sequences and recombinant envelope glycoproteins derived from non-syncytium-inducing strains than for those derived from syncytium-inducing strains.

UI MeSH Term Description Entries
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein

Related Publications

M Schutten, and J P Langedijk, and A C Andeweg, and R C Huisman, and R H Meloen, and A D Osterhaus
December 1991, Proceedings of the National Academy of Sciences of the United States of America,
M Schutten, and J P Langedijk, and A C Andeweg, and R C Huisman, and R H Meloen, and A D Osterhaus
April 1995, Journal of clinical microbiology,
M Schutten, and J P Langedijk, and A C Andeweg, and R C Huisman, and R H Meloen, and A D Osterhaus
January 1995, Journal of clinical microbiology,
M Schutten, and J P Langedijk, and A C Andeweg, and R C Huisman, and R H Meloen, and A D Osterhaus
November 1990, Proceedings of the National Academy of Sciences of the United States of America,
M Schutten, and J P Langedijk, and A C Andeweg, and R C Huisman, and R H Meloen, and A D Osterhaus
February 1995, Journal of clinical microbiology,
M Schutten, and J P Langedijk, and A C Andeweg, and R C Huisman, and R H Meloen, and A D Osterhaus
September 2004, Journal of virology,
M Schutten, and J P Langedijk, and A C Andeweg, and R C Huisman, and R H Meloen, and A D Osterhaus
November 1997, AIDS research and human retroviruses,
M Schutten, and J P Langedijk, and A C Andeweg, and R C Huisman, and R H Meloen, and A D Osterhaus
December 1994, AIDS research and human retroviruses,
M Schutten, and J P Langedijk, and A C Andeweg, and R C Huisman, and R H Meloen, and A D Osterhaus
July 2008, Journal of virology,
M Schutten, and J P Langedijk, and A C Andeweg, and R C Huisman, and R H Meloen, and A D Osterhaus
June 1992, AIDS research and human retroviruses,
Copied contents to your clipboard!